Therapeutic challenges of hepatic mucormycosis in hematologic malignancy: A case report and review of the literature

Raffaele M. Bernardo, Ananta Gurung, Dhanpat Jain, Maricar F. Malinis

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: Rare disease Background: The clinical presentation of mucormycosis can vary widely based on various host factors. Among malignancyand bone marrow transplant-associated infections, the lungs are the most common site of infection. Involvement of the gastrointestinal tract is less frequently encountered. The clinical presentation is often nonspecific, and cultures typically yield no growth, making the diagnosis challenging. Case Report: We present a case of isolated hepatic mucormycosis in the setting of neutropenic fever and abdominal pain following induction chemotherapy for the treatment of acute myeloid leukemia. The patient was treated with combination antifungal therapy with amphotericin and posaconazole without surgical resection, given the presence of multiple liver lesions. After a prolonged course of dual antifungal therapy, the size of her liver lesions improved. Unfortunately, her lymphoproliferative disorder proved fatal, following approximately 13 months of antifungal therapy. Conclusions: Among patient with mucormycosis, mortality remains high, especially in the setting of gastrointestinal involvement. Although surgical resection along with dual antifungal therapy can improve outcomes, the high mortality rate necessitates further investigation into improved diagnostic and treatment strategies including optimal antifungal therapy.

Original languageEnglish (US)
Pages (from-to)484-489
Number of pages6
JournalAmerican Journal of Case Reports
Volume17
DOIs
StatePublished - Jul 13 2016
Externally publishedYes

Fingerprint

Mucormycosis
Hematologic Neoplasms
Liver
Therapeutics
Induction Chemotherapy
Lymphoproliferative Disorders
Mortality
Amphotericin B
Rare Diseases
Infection
Acute Myeloid Leukemia
Abdominal Pain
Gastrointestinal Tract
Fever
Bone Marrow
Transplants
Lung
Growth

Keywords

  • Amphotericin B
  • Antifungal Agents
  • Leukemia, Myeloid, Acute
  • Liver Abscess
  • Mucorales
  • Mucormycosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Therapeutic challenges of hepatic mucormycosis in hematologic malignancy : A case report and review of the literature. / Bernardo, Raffaele M.; Gurung, Ananta; Jain, Dhanpat; Malinis, Maricar F.

In: American Journal of Case Reports, Vol. 17, 13.07.2016, p. 484-489.

Research output: Contribution to journalArticle

@article{3a9d118d07b64c42ad0cb65cf2979efd,
title = "Therapeutic challenges of hepatic mucormycosis in hematologic malignancy: A case report and review of the literature",
abstract = "Objective: Rare disease Background: The clinical presentation of mucormycosis can vary widely based on various host factors. Among malignancyand bone marrow transplant-associated infections, the lungs are the most common site of infection. Involvement of the gastrointestinal tract is less frequently encountered. The clinical presentation is often nonspecific, and cultures typically yield no growth, making the diagnosis challenging. Case Report: We present a case of isolated hepatic mucormycosis in the setting of neutropenic fever and abdominal pain following induction chemotherapy for the treatment of acute myeloid leukemia. The patient was treated with combination antifungal therapy with amphotericin and posaconazole without surgical resection, given the presence of multiple liver lesions. After a prolonged course of dual antifungal therapy, the size of her liver lesions improved. Unfortunately, her lymphoproliferative disorder proved fatal, following approximately 13 months of antifungal therapy. Conclusions: Among patient with mucormycosis, mortality remains high, especially in the setting of gastrointestinal involvement. Although surgical resection along with dual antifungal therapy can improve outcomes, the high mortality rate necessitates further investigation into improved diagnostic and treatment strategies including optimal antifungal therapy.",
keywords = "Amphotericin B, Antifungal Agents, Leukemia, Myeloid, Acute, Liver Abscess, Mucorales, Mucormycosis",
author = "Bernardo, {Raffaele M.} and Ananta Gurung and Dhanpat Jain and Malinis, {Maricar F.}",
year = "2016",
month = "7",
day = "13",
doi = "10.12659/AJCR.898480",
language = "English (US)",
volume = "17",
pages = "484--489",
journal = "American Journal of Case Reports",
issn = "1941-5923",
publisher = "International Scientific Literature, Inc",

}

TY - JOUR

T1 - Therapeutic challenges of hepatic mucormycosis in hematologic malignancy

T2 - A case report and review of the literature

AU - Bernardo, Raffaele M.

AU - Gurung, Ananta

AU - Jain, Dhanpat

AU - Malinis, Maricar F.

PY - 2016/7/13

Y1 - 2016/7/13

N2 - Objective: Rare disease Background: The clinical presentation of mucormycosis can vary widely based on various host factors. Among malignancyand bone marrow transplant-associated infections, the lungs are the most common site of infection. Involvement of the gastrointestinal tract is less frequently encountered. The clinical presentation is often nonspecific, and cultures typically yield no growth, making the diagnosis challenging. Case Report: We present a case of isolated hepatic mucormycosis in the setting of neutropenic fever and abdominal pain following induction chemotherapy for the treatment of acute myeloid leukemia. The patient was treated with combination antifungal therapy with amphotericin and posaconazole without surgical resection, given the presence of multiple liver lesions. After a prolonged course of dual antifungal therapy, the size of her liver lesions improved. Unfortunately, her lymphoproliferative disorder proved fatal, following approximately 13 months of antifungal therapy. Conclusions: Among patient with mucormycosis, mortality remains high, especially in the setting of gastrointestinal involvement. Although surgical resection along with dual antifungal therapy can improve outcomes, the high mortality rate necessitates further investigation into improved diagnostic and treatment strategies including optimal antifungal therapy.

AB - Objective: Rare disease Background: The clinical presentation of mucormycosis can vary widely based on various host factors. Among malignancyand bone marrow transplant-associated infections, the lungs are the most common site of infection. Involvement of the gastrointestinal tract is less frequently encountered. The clinical presentation is often nonspecific, and cultures typically yield no growth, making the diagnosis challenging. Case Report: We present a case of isolated hepatic mucormycosis in the setting of neutropenic fever and abdominal pain following induction chemotherapy for the treatment of acute myeloid leukemia. The patient was treated with combination antifungal therapy with amphotericin and posaconazole without surgical resection, given the presence of multiple liver lesions. After a prolonged course of dual antifungal therapy, the size of her liver lesions improved. Unfortunately, her lymphoproliferative disorder proved fatal, following approximately 13 months of antifungal therapy. Conclusions: Among patient with mucormycosis, mortality remains high, especially in the setting of gastrointestinal involvement. Although surgical resection along with dual antifungal therapy can improve outcomes, the high mortality rate necessitates further investigation into improved diagnostic and treatment strategies including optimal antifungal therapy.

KW - Amphotericin B

KW - Antifungal Agents

KW - Leukemia, Myeloid, Acute

KW - Liver Abscess

KW - Mucorales

KW - Mucormycosis

UR - http://www.scopus.com/inward/record.url?scp=84984996889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984996889&partnerID=8YFLogxK

U2 - 10.12659/AJCR.898480

DO - 10.12659/AJCR.898480

M3 - Article

C2 - 27406045

AN - SCOPUS:84984996889

VL - 17

SP - 484

EP - 489

JO - American Journal of Case Reports

JF - American Journal of Case Reports

SN - 1941-5923

ER -